Insider Selling: Liquidia Co. (NASDAQ:LQDA) General Counsel Sells 2,576 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,576 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now owns 486,048 shares in the company, valued at $5,399,993.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Tuesday, September 3rd, Russell Schundler sold 710 shares of Liquidia stock. The shares were sold at an average price of $9.50, for a total transaction of $6,745.00.

Liquidia Stock Up 2.2 %

Shares of LQDA opened at $11.63 on Thursday. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99. The firm’s 50 day moving average price is $10.42 and its 200 day moving average price is $11.97. The company has a market cap of $888.69 million, a P/E ratio of -7.46 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The business had revenue of $3.66 million for the quarter, compared to analysts’ expectations of $7.92 million. Research analysts forecast that Liquidia Co. will post -1.69 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently modified their holdings of the company. Creative Planning purchased a new stake in shares of Liquidia in the 3rd quarter valued at approximately $170,000. Sapient Capital LLC purchased a new stake in shares of Liquidia in the 3rd quarter valued at approximately $1,336,000. SG Americas Securities LLC purchased a new stake in shares of Liquidia in the 3rd quarter valued at approximately $210,000. Whitcomb & Hess Inc. increased its position in shares of Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after purchasing an additional 1,074 shares during the last quarter. Finally, Bluefin Capital Management LLC purchased a new stake in shares of Liquidia in the 2nd quarter valued at approximately $277,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on LQDA shares. Oppenheimer began coverage on shares of Liquidia in a report on Tuesday, June 25th. They issued a “market perform” rating on the stock. HC Wainwright decreased their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Bank of America decreased their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Scotiabank began coverage on shares of Liquidia in a report on Wednesday. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Finally, Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).